Back

Netrin-1 promotes pancreatic tumorigenesis and innervation through NEO1.

Ochiai, Y.; Kobayashi, H.; Sunagawa, M.; Baba, T.; Malagola, E.; Wu, F.; Tanaka, T.; Hata, M.; Arai, J.; Jiang, Z.; White, R. A.; Zhi, X.; Qian, J.; Waterbury, Q. T.; Tu, R.; Zheng, B.; Zeng, Y.; Zheng, H.; Zhang, P.; Li, S.; Zamechek, L. B.; LaBella, J. S.; Sugie, T.; Iida, T.; Enomoto, A.; Eltzschig, H. K.; Palermo, C. F.; Chio, I. I. C.; Olive, K. P.; Wang, T. C.

2025-07-26 cancer biology
10.1101/2025.07.22.666009 bioRxiv
Show abstract

Nerves have been shown to regulate cancer progression. However, a clear demonstration of a role for axon guidance molecules in pancreatic tumorigenesis, innervation, and metastasis has been lacking. Using murine KrasG12D-mutant pancreatic organoids, we screened axon guidance molecules by qRT-PCR, identified Ntn1 upregulation, and then verified its in vivo upregulation during pancreatic tumorigenesis in humans and mice. NTN1 and its receptor NEO1 were upregulated in epithelial cells by the Kras mutation and {beta}-adrenergic signaling, in part, through the MAPK pathway. Ex-vivo culture of celiac ganglia showed that NTN1 promoted the axonogenesis of sympathetic neurons through the nerve NEO1 receptor. In the Pdx1-Cre;LSL-KrasG12D/+ model, Ntn1 knockout decreased sympathetic innervation and the development of pancreatic intraepithelial neoplasia. Treatment of pancreatic tumor organoids with recombinant NTN1 enhanced cell growth, epithelial-mesenchymal transition (EMT), and cancer stemness with the upregulation of ZEB1 and SOX9 through NEO1-mediated activation of focal adhesion kinase (FAK). In Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+mice, Ntn1 knockout reduced innervation, FAK phosphorylation, and the features of EMT and stemness to extend mouse survival. In a liver metastasis model of PDAC (pancreatic ductal adenocarcinoma), treatment with a NTN1-neutralizing antibody or tumoral knockdown of Neo1 reduced ZEB1 and SOX9 and decreased tumor progression. In contrast, Ntn1 overexpression promoted innervation and the progression of PDAC liver metastasis. These data suggest that the NTN1/NEO1 axis is a key regulator of PDAC progression, directly influencing cancer cell stemness and EMT, while indirectly promoting tumor growth through nerves. Inhibiting the NTN1/NEO1 axis could represent a potential therapeutic approach for PDAC. Statement of SignificanceNTN1 promotes pancreatic tumorigenesis and metastasis directly and indirectly through nerves, highlighting the importance of tumor cell-nerve crosstalk in cancer. NTN1 blockade could represent a promising strategy for treating PDAC liver metastasis. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=88 SRC="FIGDIR/small/666009v1_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@ca611corg.highwire.dtl.DTLVardef@ad9264org.highwire.dtl.DTLVardef@1661c00org.highwire.dtl.DTLVardef@b86798_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Gastroenterology
40 papers in training set
Top 0.1%
18.8%
2
Gut
36 papers in training set
Top 0.1%
12.5%
3
Frontiers in Oncology
95 papers in training set
Top 1%
3.6%
4
eLife
5422 papers in training set
Top 25%
3.6%
5
Cancers
200 papers in training set
Top 2%
3.6%
6
British Journal of Cancer
42 papers in training set
Top 0.4%
3.6%
7
International Journal of Cancer
42 papers in training set
Top 0.3%
3.1%
8
The Journal of Pathology
22 papers in training set
Top 0.1%
2.1%
50% of probability mass above
9
Scientific Reports
3102 papers in training set
Top 50%
2.1%
10
Cell Death & Disease
126 papers in training set
Top 0.6%
2.1%
11
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.3%
1.9%
12
EMBO Molecular Medicine
85 papers in training set
Top 1%
1.8%
13
Neoplasia
22 papers in training set
Top 0.2%
1.8%
14
Cell Reports
1338 papers in training set
Top 23%
1.8%
15
Oncogenesis
12 papers in training set
Top 0.1%
1.8%
16
Cancer Cell
38 papers in training set
Top 1.0%
1.7%
17
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.8%
1.3%
18
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.8%
1.2%
19
BMC Cancer
52 papers in training set
Top 2%
1.1%
20
Cancer Research
116 papers in training set
Top 3%
1.0%
21
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.6%
1.0%
22
Molecular Oncology
50 papers in training set
Top 0.7%
1.0%
23
Cells
232 papers in training set
Top 4%
1.0%
24
Molecular Cancer
14 papers in training set
Top 0.8%
0.8%
25
JCI Insight
241 papers in training set
Top 6%
0.8%
26
PeerJ
261 papers in training set
Top 15%
0.8%
27
Cancer Discovery
61 papers in training set
Top 2%
0.8%
28
Journal of Translational Medicine
46 papers in training set
Top 3%
0.8%
29
Journal of Clinical Investigation
164 papers in training set
Top 6%
0.8%
30
Translational Oncology
18 papers in training set
Top 0.4%
0.8%